- Open Satellite Events will take place at the San Antonio Marriott Rivercenter
Medical Crossfire®: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer
Presented by Physicians’ Education Resource, LLC
This activity is supported by educational grants from Gilead, Menarini-Stemline, Sanofi Genzyme, and Veru, Inc.
Expanding the Spectrum of HER2-Positivity for Precision Breast Cancer Care: Clinical Implications of HER2-Low Status
Presented by Clinical Care Options, LLC
This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Clarifying the Complexities and Augmenting the Options in the Treatment of HR+/HER2- Breast Cancer: How to Build Better Skills to Make the Most of Existing and Emerging Therapies for the Benefit of Patients With HR+/HER2- MBC and EBC
Presented by PVI, PeerView Institute for Medical Education
This activity is supported by educational grants from Sanofi, Lilly, and Gilead
Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy
Presented by Clinicial Care Options, LLC
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Lilly, Merck Sharp & Dohme LLC, and Sanofi
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer
Presented by Research To Practice
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, and Seagen Inc. Additional supporters to be announced.
Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments
Presented by Society of Nuclear Medicine and Molecular Imaging
This activity is supported by educational grants from GE Healthcare and SNMMI Value Initiative
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer
Presented by Research To Practice
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Lilly, Novartis, and Sanofi. Additional supporters to be announced.